Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology..
AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF). A recent study showed that ID defined by the current guideline criteria was not associated with worse clinical outcomes, and new ID criteria was proposed in patients with HF. However, the external applicability of the new proposed criteria is unclear. We sought to investigate the applicability of the proposed ID criteria in Japanese patients with HF.
METHODS AND RESULTS: We prospectively examined 763 patients with chronic HF from a Japanese multicentre registry. The proposed ID criteria were transferrin saturation (TSAT) < 20% and serum iron ≤13 mmol/L and the guideline ID criteria were serum ferritin <100 ng/mL or, when ferritin was 100-299 ng/mL, TSAT <20%. Among all patients (456 male, mean age 71 ± 13 years), 213 (28%) and 444 (58%) met the proposed and guideline ID criteria, respectively. During a median follow-up period of 436 days (interquartile range 297-565), the primary outcome of all-cause mortality occurred in 56 (7%) patients. There was no significant difference in the primary outcome between the patients with and without guideline ID criteria (P = 0.32), whereas patients with serum iron ≤10 μmol/L showed higher mortality (P = 0.002). In multivariable Cox regressions, the proposed ID criteria, but not guideline ID criteria, were independently associated with the risk of all-cause mortality (HR 2.01, 95% CI 1.16-3.51 and HR 1.32, 95% CI 0.76-2.28, respectively), even after adjustment for covariates.
CONCLUSIONS: When defined by the proposed criteria and not the guideline criteria, ID was associated with higher mortality in patients with chronic HF, suggesting that the proposed ID criteria is applicable to the Japanese population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ESC heart failure - 10(2023), 2 vom: 03. Apr., Seite 985-994 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tada, Atsushi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-73-2 |
|---|
| Anmerkungen: |
Date Completed 30.03.2023 Date Revised 06.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ehf2.14265 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350072809 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350072809 | ||
| 003 | DE-627 | ||
| 005 | 20231226044126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ehf2.14265 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM350072809 | ||
| 035 | |a (NLM)36495060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tada, Atsushi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2023 | ||
| 500 | |a Date Revised 06.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. | ||
| 520 | |a AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF). A recent study showed that ID defined by the current guideline criteria was not associated with worse clinical outcomes, and new ID criteria was proposed in patients with HF. However, the external applicability of the new proposed criteria is unclear. We sought to investigate the applicability of the proposed ID criteria in Japanese patients with HF | ||
| 520 | |a METHODS AND RESULTS: We prospectively examined 763 patients with chronic HF from a Japanese multicentre registry. The proposed ID criteria were transferrin saturation (TSAT) < 20% and serum iron ≤13 mmol/L and the guideline ID criteria were serum ferritin <100 ng/mL or, when ferritin was 100-299 ng/mL, TSAT <20%. Among all patients (456 male, mean age 71 ± 13 years), 213 (28%) and 444 (58%) met the proposed and guideline ID criteria, respectively. During a median follow-up period of 436 days (interquartile range 297-565), the primary outcome of all-cause mortality occurred in 56 (7%) patients. There was no significant difference in the primary outcome between the patients with and without guideline ID criteria (P = 0.32), whereas patients with serum iron ≤10 μmol/L showed higher mortality (P = 0.002). In multivariable Cox regressions, the proposed ID criteria, but not guideline ID criteria, were independently associated with the risk of all-cause mortality (HR 2.01, 95% CI 1.16-3.51 and HR 1.32, 95% CI 0.76-2.28, respectively), even after adjustment for covariates | ||
| 520 | |a CONCLUSIONS: When defined by the proposed criteria and not the guideline criteria, ID was associated with higher mortality in patients with chronic HF, suggesting that the proposed ID criteria is applicable to the Japanese population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Chronic heart failure | |
| 650 | 4 | |a Criteria | |
| 650 | 4 | |a Iron deficiency | |
| 650 | 4 | |a Prognosis | |
| 650 | 7 | |a Ferritins |2 NLM | |
| 650 | 7 | |a 9007-73-2 |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 700 | 1 | |a Nagai, Toshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Koya, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Motoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ishizaka, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuguchi, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Aoyagi, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Imagawa, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuda, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Masashige |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Yoshiya |e verfasserin |4 aut | |
| 700 | 1 | |a Machida, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsutani, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Takahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Anzai, Toshihisa |e verfasserin |4 aut | |
| 700 | 0 | |a ELMSTAT-HF investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESC heart failure |d 2014 |g 10(2023), 2 vom: 03. Apr., Seite 985-994 |w (DE-627)NLM261791397 |x 2055-5822 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:2 |g day:03 |g month:04 |g pages:985-994 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ehf2.14265 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 2 |b 03 |c 04 |h 985-994 | ||